Glycosylphosphatidylinositol Anchors ofPlasmodium falciparum
Open Access
- 27 November 2000
- journal article
- Published by Rockefeller University Press in The Journal of Experimental Medicine
- Vol. 192 (11) , 1563-1576
- https://doi.org/10.1084/jem.192.11.1563
Abstract
Induction of proinflammatory cytokine responses by glycosylphosphatidylinositols (GPIs) of intraerythrocytic Plasmodium falciparum is believed to contribute to malaria pathogenesis. In this study, we purified the GPIs of P. falciparum to homogeneity and determined their structures by biochemical degradations and mass spectrometry. The parasite GPIs differ from those of the host in that they contain palmitic (major) and myristic (minor) acids at C-2 of inositol, predominantly C18:0 and C18:1 at sn-1 and sn-2, respectively, and do not contain additional phosphoethanolamine substitution in their core glycan structures. The purified parasite GPIs can induce tumor necrosis factor α release from macrophages. We also report a new finding that adults who have resistance to clinical malaria contain high levels of persistent anti-GPI antibodies, whereas susceptible children lack or have low levels of short-lived antibody response. Individuals who were not exposed to the malaria parasite completely lack anti-GPI antibodies. Absence of a persistent anti-GPI antibody response correlated with malaria-specific anemia and fever, suggesting that anti-GPI antibodies provide protection against clinical malaria. The antibodies are mainly directed against the acylated phosphoinositol portion of GPIs. These results are likely to be valuable in studies aimed at the evaluation of chemically defined structures for toxicity versus immunogenicity with implications for the development of GPI-based therapies or vaccines.Keywords
This publication has 53 references indexed in Scilit:
- Anti–Merozoite Surface Protein–1 19‐kDa IgG in Mother‐Infant Pairs Naturally Exposed toPlasmodium falciparum:Subclass Analysis with Age, Exposure to Asexual Parasitemia, and Protection against Malaria. V. The Asembo Bay Cohort ProjectThe Journal of Infectious Diseases, 2000
- Phase I/IIa Safety, Immunogenicity, and Efficacy Trial of NYVAC‐Pf7, a Pox‐Vectored, Multiantigen, Multistage Vaccine Candidate forPlasmodium falciparumMalariaThe Journal of Infectious Diseases, 1998
- ReplyParasitology Today, 1997
- Host Age as a determinant of naturally acquired immunity to Plasmodium falciparumParasitology Today, 1995
- Analysis of sequence diversity in the Plasmodium falciparum merozoite surface protein-1 (MSP-1)Molecular and Biochemical Parasitology, 1993
- The malaria vaccine: anti-parasite or anti-disease?Immunology Today, 1990
- Glycolipid anchorage of plasmodium falciparum surface antigensResearch in Immunology, 1990
- Tumor Necrosis Factor (Cachectin) as an Essential Mediator in Murine Cerebral MalariaScience, 1987